

32. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M et al (2020) Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? *Osteoporos Int* 31:2271–2286
33. Gartlehner G, Patel SV, Feltner C, et al. (2017) Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 318:2234–2249
34. Eastell R, Rosen CJ, Black DM, et al. (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 104(5):1595–1622
35. Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. *JAMA* 282:637–645
36. Barrett-Connor E, Mosca L, Collins P, et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. *N Engl J Med* 355:125–137
37. Barrett-Connor E, Cox DA, Song J, et al. (2009) Raloxifene and risk for stroke based on the framingham stroke risk score. *Am J Med* 122:754–761
38. Black DM, Cummings SR, Karpf DB et al (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet* 348:1535–1541
39. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. *JAMA*. 1998;280(24):2077–2082.
40. Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. *N Engl J Med* 343:604–610
41. Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. *N Engl J Med* 339:292–299
42. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. *JAMA* 282:1344–1352
43. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. *Osteoporos Int* 11:83–91
44. Barrionuevo PM, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab*. 2019;104(5):1623–1630.
45. McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. *N Engl J Med* 344:333–340
46. Boonen S, Orwoll ES, Wenderoth D, et al. (2009) Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. *J Bone Miner Res* 24:719–725
47. Wallach S, Cohen S, Reid DM et al (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. *Calcif Tissue Int* 67:277–285
48. Reid DM, Hughes RA, Laan RF et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. *J Bone Miner Res* 15:1006–1013
49. Delmas PD, Recker RR, Chesnut CH 3rd, et al. (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. *Osteoporos Int* 15:792–798
50. Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *J Bone Miner Res* 19:1241–1249
51. Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. *Ann Rheum Dis* 65:654–661
52. Eisman JA, Civitelli R, Adami S et al (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. *J Rheumatol* 35:488–497
53. Barrionuevo PM, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. *J Clin Endocrinol Metab*. 2019;104(5):1623–1630.
54. Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med* 356:1809–1822
55. Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. *N Engl J Med*. 2018;379(25):2407–2416.
56. Boonen S, Reginster JY, Kaufman JM et al (2012) Fracture risk and zoledronic acid therapy in men with osteoporosis. *N Engl J Med* 367:1714–1723
57. Reid DM, Devogelaer JP, Saag K et al (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 373:1253–1263
58. Lyles KW, Colon-Emeric CS, Magaziner JS et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med* 357:1799–1809
59. Reid IR, Horne AM, Mihov B, et al. (2020) Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. *J Bone Miner Res* 35:20–27
60. Cummings SR, San Martin J, McClung MR et al. (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med* 361:756–765
61. Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open label extension. *Lancet Diabetes Endocrinol* 5:513–523
62. Langdahl B, L. Teglbjaerg, C. S., Ho, P. R., et al. (2015). A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: Results from the ADAMO trial. *The Journal of Clinical Endocrinology and Metabolism*, 100(4), 1335–1342.
63. Saag, K. G., Pannacchiulli, N., Geusens, P., et al. (2019). Denosumab vs risedronate in glucocorticoid-induced osteoporosis: Final results of a 24-month randomized, double-blind, double-dummy trial. *Arthritis & Rheumatology*, 71(7), 1174–1184.
64. Smith, M. R., Egerdie, B., Hernandez, T. N. et al. (2009). Denosumab in men receiving androgen deprivation therapy for prostate cancer. *The New England Journal of Medicine*, 361(8), 745–755
65. Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. *J Bone Miner Res* 33:190–198
66. Dennison EM, Cooper C, Kanis JA, et al. (2019) Fracture risk following intermission of osteoporosis therapy. *Osteoporos Int* 30:1733–1743
67. Jähn-Rickert K, Wölfel EM, Jobke B, et al. Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation. *Front Endocrinol (Lausanne)*. 2020 May 15;11:250.
68. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. *Bone*. 2017 Dec;105:11-17.
69. Watts NB, Roux C, Modlin JF et al (2012) Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? *Osteoporos Int* 23(1): 327–337
70. Choi NK, Solomon DH, Tsacogianis TN, et al. (2017) Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. *J Bone Miner Res* 32(3):611–617
71. Black DM, Abrahamsen B, Bouxsein ML, et al. Atypical femur fractures - review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. *Endocr Rev*. 2019;40(2):333–368.
72. Starr J, Tay YKD, Shane E. Current understanding of epidemiology, pathophysiology, and management of atypical femur fractures. *Curr Osteoporos Rep*. 2018;16:519–529.
73. Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*. 2007 Oct;22(10):1479-91.
74. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res*. 2015 Jan;30(1):3-23.
75. Yarom N, Shapiro CL, Peterson DE, et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. *J Clin Oncol*. 2019 Sep 1; 37(25):2270-2290.
76. Black DM, Geiger EJ, Eastell R, et al. Atypical Femur Fracture Risk versus Fracture Prevention with Bisphosphonates. *N Engl J Med*. 2020 Aug 20;383(8):743-753.
77. Amgen (2020) (ClinicalTrials.gov Identifier: NCT00523341) <https://clinicaltrials.gov/ct2/show/study/NCT00523341>
78. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res*. 2014 Jan;29(1):1-23.
79. McKenna MJ, McKiernan FE, McGowan B et al. Identifying Incomplete Atypical Femoral Fractures With Single-Energy Absorptiometry: Declining Prevalence. *J Endocr Soc*. 2017 Feb 13;1(3):211-220
80. Adler RA, El-Hajj Fuleihan G, Bauer DC et al (2016) Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 31:16–35
81. Greenspan SL, Vujevich K, Britton C, et al. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. *Osteoporos Int*. 2018 Feb;29(2):501-506.
82. van de Laarschot DM, McKenna MJ, Abrahamsen B et al. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. *J Clin Endocrinol Metab*. 2020 May 1;105(5):1682-99.
83. Samelson EJ, Broe KE, Xu H, Yang L, Boyd S, Biver E, et al. Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. *Lancet Diabetes Endocrinol*. 2019;7(1):34-43.